DOCSLIB.ORG

Monoamine Oxidase-A in Borderline Personality Disorder and Antisocial Personality Disorder

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Monoamine Oxidase-A in Borderline Personality Disorder and Antisocial Personality Disorder MONOAMINE OXIDASE-A IN BORDERLINE PERSONALITY DISORDER AND ANTISOCIAL PERSONALITY DISORDER by Nathan J. Kolla A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy, Institute of Medical Science, University of Toronto © Copyright by Nathan J. Kolla (2015) Nathan J. Kolla Title: Monoamine Oxidase-A in Borderline Personality Disorder and Antisocial Personality Disorder Doctor of Philosophy, Institute of Medical Science, University of Toronto, 2015 ABSTRACT Monoamine oxidase A (MAO-A) is a brain enzyme that serves several physiologic functions, including metabolism of monoamine neurotransmitters and induction of pro-apoptotic signaling pathways. Increased brain MAO-A level is present in clinical disorders characterized by low mood states, whereas decreased brain MAO-A level is associated with higher trait impulsivity and aggression in healthy volunteers. Borderline personality disorder (BPD) and antisocial personality disorder (ASPD) are common psychiatric conditions that exact a high healthcare and societal burden. BPD is associated with acute episodes of severe dysphoria, and ASPD presents high levels of impulsivity and aggression. The overall aim of the thesis was to investigate MAO- A brain level in BPD and ASPD. The first experiment used [11C] harmine positron emission tomography (PET) to assess MAO-A total distribution volume (MAO-A VT), an index of MAO-A density, in females with BPD. Our results showed that MAO-A VT was elevated in the prefrontal cortex (PFC) and anterior cingulate cortex (ACC) of severe BPD compared to control groups. Greater PFC and ACC MAO-A VT was additionally associated with more severe mood symptoms and suicidality in BPD. 11 The second experiment applied [ C] harmine PET to examine MAO-A VT in ii impulsive, violent male offenders with ASPD. We found that orbitofrontal cortex and ventral striatum (VS) MAO-A VT were lower in ASPD compared to controls. Behavioral, self-report, and clinician-rated measures of impulsivity were also negatively correlated with VS MAO-A VT. The third experiment employed functional magnetic resonance imaging to measure VS resting state functional connectivity (FC) in ASPD. Our results demonstrated functional coupling between superior VS and bilateral dorsomedial prefrontal cortex that was correlated with VS MAO-A VT, and functional coupling between inferior VS and right hippocampus that was anti- correlated with VS MAO-A VT. The observed FC patterns were additionally associated with measures of impulsivity. Taken together, this body of research implicates abnormal brain MAO-A level in the pathophysiology of two related yet distinct personality disorders and their symptom clusters. Novel interventions targeting abnormal brain MAO-A level could emerge as potential new therapeutics for these disorders. iii ACKNOWLEDGEMENTS AND CONTRIBUTIONS I owe a tremendous debt of gratitude to the many individuals who offered me their steadfast support throughout graduate school. Much like the fiduciary obligation a physician has toward his patients, the PhD supervisor is entrusted with no less a responsibility in mentoring his students. I offer a very heartfelt thanks to my PhD supervisor, Dr. Jeffrey Meyer, for the undeniably positive influence he has been to me. When I reflect on all that Jeff has taught me about research and how to get the money to do it, I know that I have truly learned from a master. I would like to thank my PhD supervisory committee members, Drs. Michael Bagby and Paul Links, for their perceptive guidance throughout my degree. Paul, I have thoroughly enjoyed working together since I met you as a medical student. Mike, I hope that we are able to collaborate in the future. I wish to acknowledge all the personnel, fellows, and students in Dr. Meyer’s laboratory who contributed to my success in countless ways. In particular, I would like to thank Laura Miler for her boundless patience and helpfulness in troubleshooting laboratory issues that allowed my experiments to run all the more smoother. iv I was very fortunate to have supervised several undergraduate co-op students from the University of Toronto at Scarborough who completed consecutive work term placements at Dr. Meyer’s laboratory: Malcolm (Alex) Blagrove, Amanda Brijmohan, Charis Kellow, Jalpa Patel, Amina Hussain, and Fawn Rasquinha. This incredibly talented group of individuals was critical to the day-to-day success of the research operation and inspired me with their enthusiasm. I would like to thank Dr. Jonathan Downar and his graduate student, Katie Dunlop, who provided advice and guidance on the processing and analysis of resting state functional magnetic resonance imaging data. The emotional support I received from my parents, Ray and Val Kolla, during the tenure of my degree is just another example of the positive affirmation that has been consistently afforded to me by them. Although my parents may not have initially appreciated the reasons for my wanting to pursue a PhD, especially since in their estimation I already possessed a perfectly fine doctorate, I am very grateful for their constant encouragement and the genuine interest that they take in my work. Finally, I extend the deepest thanks to my husband, Brian G. Bachand, whose utter selflessness, irrepressible optimism, and unconditional love made completion of this work possible. Brian, I dedicate my thesis to you. v I would also like to acknowledge the following programs and/or organizations for their support: Canadian Institutes of Health Research Clinician Scientist Program, American Psychiatric Institute for Research and Education Psychiatric Research Fellowship Program, Physicians’ Services Incorporated Foundation Resident Research Grant Program, and the University of Toronto Department of Psychiatry Clinician Scientist Program. This research was funded by an operating grant from the Canadian Institutes of Health Research with support from the above agencies. vi ABSTRACT ii ACKNOWLEDGEMENTS/CONTRIBUTIONS iv TABLE OF CONTENTS viii LIST OF TABLES xv LIST OF FIGURES xvi ABBREVIATIONS xvii vii CHAPTER I ................................................................................................................. 1 1.1 Introduction .......................................................................................................... 2 1.2 General Characteristics of Monoamine Oxidase-A.............................................. 3 1.2.1 Substrate Selectivity of Monoamine Oxidase-A....................................... 3 1.2.1.1 Serotonin ............................................................................................. 4 1.2.1.2 Norepinephrine .................................................................................. 4 1.2.1.3 Dopamine ........................................................................................... 6 1.2.2 Inhibition Sensitivity of Monoamine Oxidase-A ...................................... 7 1.2.3 Distribution of Monoamine Oxidase-A In Human Brain ....................... 10 1.2.3.1 Fetal and Postnatal Levels of Monoamine Oxidase-A ..................... 10 1.2.3.2 Adult Levels of Monoamine Oxidase-A ........................................... 10 1.2.4 Physiological Functions of Monoamine Oxidase-A in Human Brain .... 11 1.2.4.1 Amine Degradation and Production of Hydrogen Peroxide ............. 11 1.2.4.2 Induction of Apoptotic Pathways...................................................... 13 1.2.5 Transcription Regulation of the Monoamine Oxidase-A Gene .............. 14 1.2.5.1 Specificity Protein 1 and R1 ............................................................. 14 1.2.5.2 Sex-determining Region Y ............................................................... 15 1.2.5.3 Glucocorticoids ................................................................................ 15 1.2.6 Monoamine Oxidase-A Genetic Polymorphisms ................................... 16 1.3. Monoamine Oxidase-A and Psychiatric Symptoms ......................................... 17 1.3.1 Monoamine Oxidase-A in Depression and Dysphoria ........................... 18 1.3.1.1 Human Studies of Monoamine Oxidase-A, Depression, and Dysphoria .......................................................................................... 18 1.3.1.1.1 Clinical Studies Linking Elevated Monoamine Oxidase-A to viii Depression................................................................................... 18 1.3.1.1.2 Postmortem Studies of Monoamine Oxidase-A ......................... 20 1.3.1.1.3 Molecular Imaging Studies of Monoamine Oxidase-A in Depression................................................................................... 20 1.3.1.1.3.1 [11C] Harmine Positron Emission Tomography .................... 21 1.3.1.1.3.2 Monoamine Oxidase-A Total Distribution Volume ............. 26 1.3.1.1.4 Genetic Studies of Monoamine Oxidase-A and Depressive Illness .......................................................................................... 28 1.3.1.2 Animal Studies of Monoamine Oxidase-A and Depressive Symptoms ......................................................................................... 29 1.3.1.2.1 Preclinical Studies of Monoamine Oxidase-A and Depressive Symptoms ................................................................................... 29 1.3.2 Monoamine Oxidase-A in Impulsivity and Aggression ......................... 31 1.3.2.1 Human Studies of Monoamine Oxidase-A, Impulsivity, and Aggression .......................................................................................
Load more

Recommended publications
  • Bibliography & Appendix
    Bibliography Abou-Sleiman, P. M., Muqit, M. M. K. & Wood, N. W. 2006. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nature reviews neuroscience. 7: 207- 219. Agid, Y., Destée, A., Durif, F., Montastruc, J. L. & Pollak, P. 1997. Tolcapone, romocriptine, and Parkinson’s disease. The lancet . 350: 712-713. Anderson, M. C., Hasan, F., Mccrodden, J. M. & Tipton, K. F. 1993. Monoamine oxidase inhibitors and the cheese effect. Neurochemical research. 18 : 1145-1149. Avner, D. L. 2000. Clinical experience with pantoprazole in gastroesophageal reflux disease. Clinical therapeutics . 22: 1169-1185. Bach, A. W., Lan, N. C., Johnson, D. L., Abell, C. W., Bembenek, M. E., Kwan, S. W., Seeburg, P. H. & Shih, J. C. 1988. cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proceedings of the national academy of sciences of the United States of America . 85: 4934-4938. Baker, G. B., Coutts, R. T., Mckenna, K. F. & Sherry-Mckenna, R. L. 1992. Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review. Journal of psychiatry and neuroscience. 17 : 206-214. Barden, T. P., Peter, J. B. & Merkatz, I. R. 1980. Ritodrine hydrochloride: a betamimetic agent for use in preterm labor. Journal of the American college of obstetricians and gynecologists . 56: 1-6. Bergström, M., Westerberg, G., Németh, G., Traut, M., Gross, G., Greger, G., Müller- Peltzer, H., Safer, A., Eckernäs, S. Å., Grahnér, A. & Långström, B. 1997. MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: in vivo studies with positron emission tomography.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • The Influence of Palmatine Isolated from Berberis Sibirica Radix On
    cells Article The Influence of Palmatine Isolated from Berberis sibirica Radix on Pentylenetetrazole-Induced Seizures in Zebrafish Kinga Gawel 1,2,* , Wirginia Kukula-Koch 3 , Dorota Nieoczym 4, Katarzyna Stepnik 5 , Wietske van der Ent 1, Nancy Saana Banono 1 , Dominik Tarabasz 3, Waldemar A. Turski 2 and Camila V. Esguerra 1 1 Chemical Neuroscience Group, Faculty of Medicine, Centre for Molecular Medicine Norway, University of Oslo, Gaustadalléen 21, 0349 Oslo, Norway; [email protected] (W.v.d.E.); [email protected] (N.S.B.); [email protected] (C.V.E.) 2 Department of Experimental and Clinical Pharmacology, Medical University of Lublin, Jaczewskiego Str. 8b, 20-090 Lublin, Poland; [email protected] 3 Chair and Department of Pharmacognosy, Medical University of Lublin, 1, Chodzki Str. 1, 20-093 Lublin, Poland; [email protected] (W.K.-K.); [email protected] (D.T.) 4 Department of Animal Physiology and Pharmacology, Institute of Biology and Biochemistry, Faculty of Biology and Biotechnology, Maria Curie-Skłodowska University, Akademicka Str. 19, 20-033 Lublin, Poland; [email protected] 5 Department of Physical Chemistry, Institute of Chemical Sciences, Faculty of Chemistry, Maria Curie-Skłodowska University, Pl. M. Curie-Skłodowskiej 3/243, 20-031 Lublin, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-81448-6454 Received: 28 April 2020; Accepted: 14 May 2020; Published: 16 May 2020 Abstract: Palmatine (PALM) and berberine (BERB) are widely identified isoquinoline alkaloids among the representatives of the Berberidaceae botanical family. The antiseizure activity of BERB was shown previously in experimental epilepsy models.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • The Relationship of Alcohol Dependence to Monoamine Oxidase A
    The Relationship of Alcohol Dependence to Monoamine Oxidase A by Brittany Matthews A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Department of Pharmacology and Toxicology University of Toronto © Copyright by Brittany Matthews 2015 The Relationship of Alcohol Dependence to Monoamine Oxidase A Brittany Matthews Doctor of Philosophy Department of Pharmacology and Toxicology University of Toronto 2015 Abstract Background: Alcohol dependence (AD) is a substance abuse disorder characterized by compulsive alcohol seeking and intake, combined with a negative emotional state during withdrawal. AD is also associated with markers of apoptosis and/or oxidative stress across multiple organs. Monoamine oxidase A (MAO-A) is an important enzyme that participates in the cellular response to oxidative stress, and is elevated during major depressive episodes, somewhat more robustly in the prefrontal cortex (PFC) and anterior cingulate cortex (ACC). It is unknown whether MAO-A levels are abnormal in AD. The current studies examine whether: i) MAO-A level is elevated in the PFC and ACC in AD in humans. ii) Chronic harman exposure, a MAO-A inhibitor found in alcoholic beverages, upregulates MAO-A in the PFC and ACC of rodents. iii) Chronic alcohol exposure upregulates MAO-A in the PFC and ACC of rodents. Methods: i) Sixteen participants with AD underwent [ 11 C]-harmine positron emission tomography to determine MAO-A distribution volume (VT), an index of MAO-A level. ii ii) Rats were treated with harman for 21 days (0, 2, 5, 15 mg/kg/day) via osmotic minipump. MAO-A protein and activity levels, measured with Western blot and a spectrophotometric assay respectively, were assessed immediately and after 8-hour withdrawal.
    [Show full text]
  • Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
    (19) TZZ ¥__T (11) EP 2 998 314 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 23.03.2016 Bulletin 2016/12 C07K 7/08 (2006.01) A61K 38/10 (2006.01) A61K 47/48 (2006.01) A61P 1/00 (2006.01) (21) Application number: 15190713.6 (22) Date of filing: 04.06.2008 (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • SHAILUBHAI, Kunwar HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT Audubon, PA 19402 (US) RO SE SI SK TR • JACOB, Gary S. New York, NY 10028 (US) (30) Priority: 04.06.2007 US 933194 P (74) Representative: Cooley (UK) LLP (62) Document number(s) of the earlier application(s) in Dashwood accordance with Art. 76 EPC: 69 Old Broad Street 12162903.4 / 2 527 360 London EC2M 1QS (GB) 08770135.5 / 2 170 930 Remarks: (71) Applicant: Synergy Pharmaceuticals Inc. This application was filed on 21-10-2015 as a New York, NY 10170 (US) divisional application to the application mentioned under INID code 62. (54) AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS (57) The invention provides novel guanylate cycla- esterase. The gastrointestinal disorder may be classified se-C agonist peptides and their use in the treatment of as either irritable bowel syndrome, constipation, or ex- human diseases including gastrointestinal disorders, in- cessive acidity etc. The gastrointestinal disease may be flammation or cancer (e.g., a gastrointestinal cancer).
    [Show full text]
  • Imaging Dopamine
    This page intentionally left blank Imaging Dopamine Since its discovery 50 years ago, brain dopamine has been implicated in the control of movement and cognition, and has emerged as a key factor in diverse brain diseases such as Parkinson’s disease, schizophrenia, and drug addiction. This book is an illustrated biography of the dopamine molecule, beginning with an account of its synthesis in brain, and then describing its storage, release and signalling mechanisms, and its ultimate metabolic breakdown. Using color illustrations of positron emission tomography (PET) scans, each chapter presents a specific stage in the biochemical pathway for dopamine. Writing for researchers and graduate students, Paul Cumming presents an overview of all that has been learned about dopamine through molecular imaging, a technology which allows the measurement of formerly invisible processes in the living brain. He reviews current technical controversies in the interpretation of dopamine imaging and presents key results illuminating the roles of brain dopamine in illness and health. Paul Cumming is Professor in the Department of Nuclear Medicine at Ludwig- Maximilian University in Munich, Germany. He currently serves on the editorial boards of the journals Synapse, Journal of Cerebral Blood Flow and Metabolism, and NeuroImage. Imaging Dopamine PAUL CUMMING Ludwig-Maximilian University, Munich, Germany CAMBRIDGE UNIVERSITY PRESS Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, São Paulo Cambridge University Press The Edinburgh Building, Cambridge CB2 8RU, UK Published in the United States of America by Cambridge University Press, New York www.cambridge.org Information on this title: www.cambridge.org/9780521790024 © P. Cumming 2009 This publication is in copyright.
    [Show full text]
  • (12) United States Patent (Lo) Patent No.: US 8,480,637 B2
    111111111111111111111111111111111111111111111111111111111111111111111111 (12) United States Patent (lo) Patent No.: US 8,480,637 B2 Ferrari et al. (45) Date of Patent : Jul. 9, 2013 (54) NANOCHANNELED DEVICE AND RELATED USPC .................. 604/264; 907/700, 902, 904, 906 METHODS See application file for complete search history. (75) Inventors: Mauro Ferrari, Houston, TX (US); (56) References Cited Xuewu Liu, Sugar Land, TX (US); Alessandro Grattoni, Houston, TX U.S. PATENT DOCUMENTS (US); Daniel Fine, Austin, TX (US); 5,651,900 A 7/1997 Keller et al . .................... 216/56 Randy Goodall, Austin, TX (US); 5,728,396 A 3/1998 Peery et al . ................... 424/422 Sharath Hosali, Austin, TX (US); Ryan 5,770,076 A 6/1998 Chu et al ....................... 210/490 5,798,042 A 8/1998 Chu et al ....................... 210/490 Medema, Pflugerville, TX (US); Lee 5,893,974 A 4/1999 Keller et al . .................. 510/483 Hudson, Elgin, TX (US) 5,938,923 A 8/1999 Tu et al . ........................ 210/490 5,948,255 A * 9/1999 Keller et al . ............. 210/321.84 (73) Assignees: The Board of Regents of the University 5,985,164 A 11/1999 Chu et al ......................... 516/41 of Texas System, Austin, TX (US); The 5,985,328 A 11/1999 Chu et al ....................... 424/489 Ohio State University Research (Continued) Foundation, Columbus, OH (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this WO WO 2004/036623 4/2004 WO WO 2006/113860 10/2006 patent is extended or adjusted under 35 WO WO 2009/149362 12/2009 U.S.C. 154(b) by 612 days.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0010208A1 Shashoua Et Al
    US 2002001 0208A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0010208A1 Shashoua et al. (43) Pub. Date: Jan. 24, 2002 (54) DHA-PHARMACEUTICAL AGENT Related U.S. Application Data CONJUGATES OF TAXANES (63) Continuation of application No. 09/135,291, filed on (76) Inventors: Victor Shashoua, Brookline, MA (US); Aug. 17, 1998, now abandoned, which is a continu Charles Swindell, Merion, PA (US); ation of application No. 08/651,312, filed on May 22, Nigel Webb, Bryn Mawr, PA (US); 1996, now Pat. No. 5,795,909. Matthews Bradley, Layton, PA (US) Publication Classification Correspondence Address: Edward R. Gates, Esq. (51) Int. Cl." ............................................ A61K 31/337 Wolf, Greenfield & Sacks, P.C. (52) U.S. Cl. .............................................................. 514/449 600 Atlantic Avenue Boston, MA 02210 (US) (57) ABSTRACT The invention provides conjugates of cis-docosahexaenoic (21) Appl. No.: 09/846,838 acid and pharmaceutical agents useful in treating noncentral nervous System conditions. Methods for Selectively target 22) Filled: Mayy 1, 2001 ingg pharmaceuticalp agents9. to desired tissues are pprovided. Patent Application Publication Jan. 24, 2002 Sheet 1 of 14 US 2002/0010208A1 1 OO 5 O -5OO - 1 OO-9 -8 -7 -6 -5 -4 LOG-10 OF SAMPLE CONCENTRATION (MOLAR) CCRF-CEM-o- SR ----- RPM-8226----- K-562- - -A - - HL-60 (TB) -g- - MOLT4: ... O Fig. 1 1 OO 5 O -5OO -1 O O -8 -7 -6 -5 -4 -- 9 LOGo OF SAMPLE CONCENTRATION (MOLAR) A549/ATCC-o-NS326. NCEKVX 28. --Q-- NCI-H322M-...-a---Eidsf8::... NC-H522--O-- HOP-62---Fig. 2 a-- NC-H460.-------- Patent Application Publication Jan.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
    Molecules 2016, 21, 75; doi:10.3390/molecules21010075 S1 of S110 Supplementary Materials: Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs Fei Mao 1, Wei Ni 1, Xiang Xu 1, Hui Wang 1, Jing Wang 1, Min Ji 1 and Jian Li * Table S1. Common names, indications, CAS Registry Numbers and molecular formulas of 6891 approved drugs. Common Name Indication CAS Number Oral Molecular Formula Abacavir Antiviral 136470-78-5 Y C14H18N6O Abafungin Antifungal 129639-79-8 C21H22N4OS Abamectin Component B1a Anthelminithic 65195-55-3 C48H72O14 Abamectin Component B1b Anthelminithic 65195-56-4 C47H70O14 Abanoquil Adrenergic 90402-40-7 C22H25N3O4 Abaperidone Antipsychotic 183849-43-6 C25H25FN2O5 Abecarnil Anxiolytic 111841-85-1 Y C24H24N2O4 Abiraterone Antineoplastic 154229-19-3 Y C24H31NO Abitesartan Antihypertensive 137882-98-5 C26H31N5O3 Ablukast Bronchodilator 96566-25-5 C28H34O8 Abunidazole Antifungal 91017-58-2 C15H19N3O4 Acadesine Cardiotonic 2627-69-2 Y C9H14N4O5 Acamprosate Alcohol Deterrant 77337-76-9 Y C5H11NO4S Acaprazine Nootropic 55485-20-6 Y C15H21Cl2N3O Acarbose Antidiabetic 56180-94-0 Y C25H43NO18 Acebrochol Steroid 514-50-1 C29H48Br2O2 Acebutolol Antihypertensive 37517-30-9 Y C18H28N2O4 Acecainide Antiarrhythmic 32795-44-1 Y C15H23N3O2 Acecarbromal Sedative 77-66-7 Y C9H15BrN2O3 Aceclidine Cholinergic 827-61-2 C9H15NO2 Aceclofenac Antiinflammatory 89796-99-6 Y C16H13Cl2NO4 Acedapsone Antibiotic 77-46-3 C16H16N2O4S Acediasulfone Sodium Antibiotic 80-03-5 C14H14N2O4S Acedoben Nootropic 556-08-1 C9H9NO3 Acefluranol Steroid
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8.263,125 B2 Vaya Et Al
    US008263125B2 (12) United States Patent (10) Patent No.: US 8.263,125 B2 Vaya et al. (45) Date of Patent: *Sep. 11, 2012 (54) DOSAGE FORM FOR HIGH DOSE-HIGH (52) U.S. Cl. ......... 424/469: 424/464; 424/465; 424/468 SOLUBLITY ACTIVE INGREDIENTS THAT (58) Field of Classification Search ........................ None PROVIDES FOR MIMEDIATE RELEASE AND See application file for complete search history. MODIFIED RELEASE OF THE ACTIVE INGREDIENTS (56) References Cited (75) Inventors: Navin Vaya, Gujarat (IN); Rajesh Singh Karan, Gujarat (IN); Sunil Sadanand U.S. PATENT DOCUMENTS Nadkarni, Gujarat (IN); Vinod Kumar 3,048,526 A * 8, 1962 Boswell ........................ 424,472 3,336,200 A 8, 1967 Krause et al. Gupta, Gujarat (IN) 4,139,589 A * 2/1979 Beringer et al. ... ... 264/250 4,503,031 A * 3/1985 Glassman ...... ... 424/467 (73) Assignee: Torrent Pharmaceuticals Limited, 4,996,061 A * 2/1991 Webb et al. ... ... 424/475 Ahmedabad (IN) 5,445,829 A * 8/1995 Paradissis et al. ... 424/480 5,738,874. A * 4/1998 Conte et al. ........ ... 424/472 (*) Notice: Subject to any disclaimer, the term of this 5,840,332 A * 1 1/1998 Lerner et al. .................. 424/464 5,985,843. A 1 1/1999 Higo et al. patent is extended or adjusted under 35 6,001,391 A 12/1999 Zeidler et al. U.S.C. 154(b) by 0 days. 6,238,699 B1 5, 2001 Rubin 6,372.254 B1 * 4/2002 Ting et al. ...... ... 424/473 This patent is Subject to a terminal dis 6,660,300 B1* 12/2003 Timmins et al.
    [Show full text]